Drug Profile
AS 1763
Alternative Names: AS-1763; BN-102; CB-1763Latest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Carna Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- No development reported Diffuse large B cell lymphoma
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a preclinical studies in Chronic lymphocytic leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 01 Aug 2023 Phase-I clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (PO) (NCT05602363)
- 01 Aug 2023 Phase-I clinical trials in Non-Hodgkin's-lymphoma (Second-line therapy or greater) in USA (PO) (NCT05602363)